Last checked at 10 Apr 2017 15:26
10 April 2017 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors and PDMRs under the Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP') on 6 April 2017. The vesting period of these options is subject to certain performance criteria over a three year period.
Director/PDMR | Options prior to grant | Options granted | Resultant holding |
Chris Meredith Chief Executive Officer | 968,436 | 109,571
| 1,078,007
|
Mary Tavener Chief Financial Officer | 591,199 | 84,762
| 675,961
|
Simon Coates PDMR | 91,864 | 17,891 | 109,755
|
Rose Guang PDMR | 138,011 | 24,067
| 162,078
|
Eddie Johnson PDMR | 120,364 | 23,775
| 144,139
|
Pieter van Hoof PDMR | 121,505 | 23,428
| 144,933
|
Becky Walmsley PDMR | 50,000 | 23,082
| 73,082
|
Jeff Willis PDMR | 132,044 | 40,550
| 172,594
|
Advanced Medical Solutions Group plc also announces that on 6 April 2017, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors under the Advanced Medical Solutions Deferred Annual Bonus Plan (the '2014 DAB').
This award is in respect of the part of their bonus that the Directors and PDMRs are compulsorily required to defer for the 2016 financial year. These options vest at the end of three years.
Director/PDMR | Options prior to grant | Options granted | Resultant holding |
Chris Meredith Chief Executive Officer | 82,218 | 23,369 | 105,587 |
Mary Tavener Chief Financial Officer | 57,870 | 15,065 | 72,935 |
Simon Coates PDMR | 4,438 | 3,306 | 7,744 |
Rose Guang PDMR | 12,586 | 4,612 | 17,198 |
Eddie Johnson PDMR | 14,803 | 4,556 | 19,359 |
Pieter van Hoof PDMR | 13,490 | 4,329 | 17,819 |
Becky Walmsley PDMR | 1,067 | 4,114 | 5,181 |
Jeff Willis PDMR | 17,996 | 5,535 | 23,531 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 109,571 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 23,369 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Mary Tavener | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 84,762 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 15,065 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Simon Coates | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 17,891 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 3,306 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Rose Guang | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 24,067 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 4,612 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Eddie Johnson | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 23,775 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 4,556 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Pieter van Hoof | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 23,428 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 4,329 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Becky Walmsley | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 23,082 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 4,114 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Jeff Willis | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Grant of 40,550 options under the Advanced Medical Solutions Long Term Incentive Plan on 6 April 2017 · Grant of 5,535 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 6 April 2017 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 06/04/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
- End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.